Assessment of renal function
The measurements of serum creatinine concentrations were planned at baseline, 6h, 12h, 24h, 48h, 2 weeks, 6 weeks, and 4 months after PCI. 2 For patients who were returned to their a referring center after PCI, creatinine concentration measurements during hospital admission and up to four months after PCI were obtained. When more than one measurement was available at a specific time point, the measurement that was nearest to the designated time point was used for analysis.
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration study equation 4 , as has been suggested to estimate the GFR more accurate than the simplified Modification of Diet in Renal Disease formula in patients without severe renal impairment. 5 Contrast-induced acute kidney injury was defined as an increase in serum creatinine of ≥0.3 mg/dL (27 μmol/L), or a 25% relative rise in creatinine, within 48 hours after the start of the PCI procedure. 6 Time of lidocaine injection defined the start of the PCI procedure. If unavailable, arrival time at the catheterization lab was used. The application of a closure device defined the end of the procedure. The extent of myocardial damage was estimated by calculating the area under the curve of CK and the myocardial band of CK from baseline until 24 hours after PCI.
Statistical analysis
Normally distributed continuous data are presented as means with standard error, unless stated otherwise, and differences were assessed using the Student's t-test. If normality could not be assumed, the data are presented as medians with interquartile range, and differences were assessed using the Mann-Whitney U test. Categorical data are presented as frequencies with percentages, and differences were assessed using the chi-square or the Fisher exact test, when appropriate.
To estimate and compare the effect of metformin on renal function, mixed-effects repeated measures analysis with random slope and intercept was performed. This type of analysis operates using estimation techniques that allow for incomplete data. Age, gender, baseline NT-proBNP concentration, and myocardial blush grade after PCI were, based on the statistical plan of the main study, considered as covariables in relation to the renal function. 1 Only significant covariables were used as fixed effects in the final multivariate model. Individual patients were considered as a random effect. The covariance matrix of residuals used in the model was unstructured.
The independent predictors of CI-AKI were identified by a backward-stepwise logistic regression model using an entry level of significance of 0.1. Randomization to metformin or placebo, gender, age, contrast dose, eGFR at baseline, and anemia (hemoglobin (Hb) <13.7 mg/dl (<8.5 mmol/L) in men and Hb <12.1 mg/dl (<7.5 mmol/L) in women) were previously associated with the development of CI-AKI and were therefore forced in the multivariate analysis in addition to risk factors found in the univariate analysis.
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All reported P-values are 2-sided and P<0.05 was considered statistically significant, except for interactions in which P<0.10 was considered significant. Since this study concerns a post-hoc analysis of a previously conducted randomized controlled trial, no sample size calculation was made. Values are expressed as no (%). ARB angiotensin-receptor blocker.
Online Resource 8 -Presented are least-squares means ± standard error from the mixed-effects repeated measurements model with a random intercept and slope. Individual patients were considered as random effects and the following were fixed effects: age, baseline N-terminal pro-B-type natriuretic peptide concentration, development of CI-AKI, and treatment allocation. We assumed an unstructured covariance structure among serial estimated glomerular filtration rate values (eGFR). No significant difference was observed for the overall interaction of CI-AKI, time and allocated treatment (P=0.14). There was an expected overall interaction between the occurrence of CI-AKI and the change in eGFR over the first 48 hours (P=0.021), but there was no difference between randomized treatments (P=0.13). At the end of follow up, eGFR did not differ between patients on placebo or metformin, neither in the CI-AKI group (P=0.34) nor the no CI-AKI group (P=0.66).
